<DOC>
	<DOCNO>NCT00066248</DOCNO>
	<brief_summary>RATIONALE : Cyproheptadine megestrol may improve appetite help prevent weight loss child cancer . PURPOSE : This phase II trial study well cyproheptadine megestrol work improve appetite prevent weight loss child cachexia cause cancer cancer treatment .</brief_summary>
	<brief_title>Cyproheptadine Megestrol Preventing Weight Loss Children With Cachexia Caused By Cancer Cancer Treatment</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy cyproheptadine prevent weight loss child cancer cancer treatment-related cachexia . - Determine efficacy megestrol prevent weight loss patient n't respond cyproheptadine . - Determine drug affect body protein fat level patient . OUTLINE : Patients receive oral cyproheptadine twice daily 4 week absence unacceptable weight loss toxicity . Patients present weight loss 4 week receive oral megestrol daily 4 week absence unacceptable weight loss toxicity . Patients respond either cyproheptadine megestrol may continue treatment discretion treat physician . Patients follow 4 week . PROJECTED ACCRUAL : A total 70 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<mesh_term>Cyproheptadine</mesh_term>
	<criteria>INCLUSION CRITERIA : Any cachectic patient weight loss presume secondary cancer cancer relate therapy eligible . Cachexia define one following : documented history weight loss &gt; 5 % drop growth rate two percentile rank standard growth chart , weight height less tenth percentile . Patients newly diagnose relapsed cancer type , include brain tumor . Patients receive active palliative therapy eligible . If patient complete treatment cancer ( surgery , chemotherapy , radiotherapy ) within 8 week study registration , also eligible . Patients must â‰¥ 2 year &lt; 21 year age time admission study . Patients must predict life expectancy least eight week . EXCLUSION CRITERIA : Patients currently take take Periactin and/or Megace past three week eligible . Patients receive corticosteroid monoamine oxidase ( MAO ) inhibitor therapy . ( Intermittent steroid use permit IF anticipate administer 7 day 4 week period . Calculate anticipate intermittent steroid use 4week interval 8week period study agent may administer ( 4 week Periactin potentially 4 week Megace . Patients receive parenteral nutrition tube feeding within 1 week start protocol patient expect require parenteral nutrition tube feeding 4week course study . Patients take dronabinol ( Marinol ) appetitestimulating medication past three week patient expect prescribed appetitestimulating medication 4week course study . Patients hormone sensitive tumor specifically meningiomas , breast cancer , ovarian cancer , endometrial carcinoma.31 , 32 Children neurofibromatosis , type I II , risk development meningioma thus exclude study.32 Children glaucoma , chronic persistent asthma , gastrointestinal ( GI ) genitourinary ( GU ) obstruction . Patients recurrent and/or persistent hypertension , define blood pressure value &gt; 20 % normal . Patients thromboembolic disease , congestive heart failure , peripheral edema . Patients pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>cachexia</keyword>
	<keyword>unspecified childhood solid tumor</keyword>
	<keyword>childhood spinal cord neoplasm</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood visual pathway glioma</keyword>
	<keyword>hypothalamic glioma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>untreated childhood visual pathway</keyword>
	<keyword>childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia</keyword>
	<keyword>myeloid malignancy</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
</DOC>